Investigators are seeking participants with relapsing-remitting MS for a large, international phase III clinical trial to evaluate the effectiveness and safety of a potential oral MS therapy, known as fingolimod or FTY720.
The study called FREEDOMS, (FTY720 Research Evaluation Daily Oral efficacy in MS), will last 24-months and compare two dosage levels of fingolimod to placebo. Approximately 1,250 people with relapsing-remitting MS will participate at 125 centres worldwide, including 10 in Canada. The study is sponsored by Novartis.
The study will include people with relapsing-remitting MS between the ages of 18 and 55 who have experienced at least one relapse during the past year, or two relapses in the past two years and meet the study eligibility criteria.
Results from a previous smaller study found after six months of treatment, fingolimod reduced the rate of clinical relapses by more than 50 percent and reduced inflammatory activity as measured by MRI by up to 80 percent compared to placebo.
For more information about the study, please contact one of the participating Canadian clinical trial sites listed below or visit www.MSClinicalTrials.com (Novartis website; English only).Some of the sites will be using Internet-based recruitment, starting in September 2006. Information about the e-recruitment process will be provided when it is available.
Canadian clinical trial sites
St. Michael's Hospital, Toronto, Dr. Paul O'Connor, 416-864-5830
University of British Columbia, Vancouver, Wendy Morrison, Study Coordinator, 604-822-1756
Kingston General Hospital, MS Clinic, Kingston, Dr. Donald G. Brunet or Vee McBride 613-548-2308
University of Saskatchewan, Regina, Felix Veloso, Principal Investigator 306-525-3586
Dalhousie University, MS Research Unit, Halifax, Trudy L. Campbell, 902-473-7947
University of Calgary, MS Clinical Research Program, Calgary, Janet Moores, Study Coordinator, 403-944-1802
Nepean Medical Centre, Ottawa, Isabelle D. Bedirian, Clinical Trials Coordinator, 613-224-1223
Health Sciences Centre, Winnipeg, Dr. Maria Melanson, 204-787-4778
Investigators are seeking participants with relapsing-remitting MS for a large, international phase III clinical trial to evaluate the effectiveness and safety of a potential oral MS therapy, known as fingolimod or FTY720.
The study called FREEDOMS, (FTY720 Research Evaluation Daily Oral efficacy in MS), will last 24-months and compare two dosage levels of fingolimod to placebo. Approximately 1,250 people with relapsing-remitting MS will participate at 125 centres worldwide, including 10 in Canada. The study is sponsored by Novartis.
The study will include people with relapsing-remitting MS between the ages of 18 and 55 who have experienced at least one relapse during the past year, or two relapses in the past two years and meet the study eligibility criteria.
Results from a previous smaller study found after six months of treatment, fingolimod reduced the rate of clinical relapses by more than 50 percent and reduced inflammatory activity as measured by MRI by up to 80 percent compared to placebo.
For more information about the study, please contact one of the participating Canadian clinical trial sites listed below or visit www.MSClinicalTrials.com (Novartis website; English only).Some of the sites will be using Internet-based recruitment, starting in September 2006. Information about the e-recruitment process will be provided when it is available.
Canadian clinical trial sites
St. Michael's Hospital, Toronto, Dr. Paul O'Connor, 416-864-5830
University of British Columbia, Vancouver, Wendy Morrison, Study Coordinator, 604-822-1756
Kingston General Hospital, MS Clinic, Kingston, Dr. Donald G. Brunet or Vee McBride 613-548-2308
University of Saskatchewan, Regina, Felix Veloso, Principal Investigator 306-525-3586
Dalhousie University, MS Research Unit, Halifax, Trudy L. Campbell, 902-473-7947
University of Calgary, MS Clinical Research Program, Calgary, Janet Moores, Study Coordinator, 403-944-1802
Nepean Medical Centre, Ottawa, Isabelle D. Bedirian, Clinical Trials Coordinator, 613-224-1223
Health Sciences Centre, Winnipeg, Dr. Maria Melanson, 204-787-4778